A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma

TY - JOUR

T1 - A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma

AU - Lee, Hans C.

AU - Feng, Lei

AU - Oriabure, Onyeka

AU - Graham, Vivian

AU - Chen, Wendy

AU - Badillo, Maria

AU - Lu, Rebecca

AU - Lee, Hun J.

AU - Jain, Preetesh

AU - Manasanch, Elisabet E.

AU - Orlowski, Robert Z.

AU - Wang, Michael L.

N1 - Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672). H.C.L. and R.Z.O. would like to acknowledge support from the Baer Family Fund. H.C.L would like to acknowledge support from the Goff‐Street Foundation. R.Z.O., the Florence Maude Thomas Cancer Research Professor, would like to acknowledge funding from the National Cancer Institute (R01s CA184464 and CA194264), the Leukemia & Lymphoma Society Specialized Center of Research (SCOR‐12206‐17), and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. M.L.W., the Puddin Clarke Endowed Professor for Myeloma Research, would like to acknowledge funding from the Nancy/Steve Fox Research Fund. This is an investigator‐initiated study sponsored by The University of Texas MD Anderson Cancer Center. Study funding was provided by Amgen, Inc who also provided carfilzomib. Funding Information: E.E.M. declares consulting fees from Takeda, Celgene, Sanofi, GlaxoKlineSmith, and Adaptive Biotechnologies and research funding from Sanofi, Quest Diagnostics, Novartis, JW Pharma, and Merck. Funding Information: R.Z.O. declares laboratory research funding from BioTheryX, and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi‐Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol‐Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi‐Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and as a consultant for STATinMED Research. Finally, RZO is a Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not bear on the current manuscript. Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672). H.C.L. and R.Z.O. would like to acknowledge support from the Baer Family Fund. H.C.L would like to acknowledge support from the Goff-Street Foundation. R.Z.O., the Florence Maude Thomas Cancer Research Professor, would like to acknowledge funding from the National Cancer Institute (R01s CA184464 and CA194264), the Leukemia & Lymphoma Society Specialized Center of Research (SCOR-12206-17), and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. M.L.W., the Puddin Clarke Endowed Professor for Myeloma Research, would like to acknowledge funding from the Nancy/Steve Fox Research Fund. This is an investigator-initiated study sponsored by The University of Texas MD Anderson Cancer Center. Study funding was provided by Amgen, Inc who also provided carfilzomib. Funding Information: H.C.L. declares consulting fees from Amgen, Celgene, Genentech, GlaxoKlineSmith, Janssen, Sanofi, and Takeda and research funding from Amgen, Celgene, Daiichi Sankyo, GlaxoKlineSmith, Janssen, Regeneron, and Takeda.

PY - 2021/7/1

Y1 - 2021/7/1

UR - http://www.scopus.com/inward/record.url?scp=85104825639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104825639&partnerID=8YFLogxK

U2 - 10.1002/ajh.26178

DO - 10.1002/ajh.26178

M3 - Letter

C2 - 33811767

AN - SCOPUS:85104825639

SN - 0361-8609

VL - 96

SP - E243-E246

JO - American journal of hematology

JF - American journal of hematology

IS - 7

ER -